In the wake of Google Inc.'s (NASDAQ:GOOG) earnings announcement last week, all the analysts who follow GOOG (which opened at $467 this morning) have tweaked their speadsheets and come up with revised, 12-month price targets. According to Henry Blodget, Slate's star analyst-turned-columnist, these targets range from $415 to $650, and none of them is worth a grain of salt.
Blodget has a piece in Slate today about the myriad problems with price targets. Blodget has been highly critical of the securities industry since he was banned for life, and you can see where he's coming from. After all, he knows how the sausage is made, and also how suspect price targets are because of their inherent paradox. Any investment professional will tell you that past performance is no guarantee of future results, but the metrics used to predict a price target (or future results) are all based on past performance. And since each metric is not much more than an educated guess, a price target is not much more than a composite guess based on guesswork. It's like a photocopy of a photocopy -- after a while, you start to lose resolution.
If you want to buy into GOOG, do it because it's a juggernaut, a core holding for anyone who wants a long-term investment in the future of the internet. Not because someone thinks it will be at a certain price at a certain time. Especially since, given GOOG's volatility over the past year, odds are that $650 price target will be revised many times before 12 months is over.
Last updated: February 13, 2012: 09:32 AM
Hot Stocks
DailyFinance Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- SanDisk volatility low into analyst day and sales outlook
- Obama budget requests increase in Pell Grants, Inside Higher Education says
- Stoneridge sees 2012 EPS $1.10-$1.30 vs. consensus $1.13
- Stoneridge Q2 results include $1.72/sh in gains
- Stoneridge reports Q4 diluted EPS $1.56 vs. consensus 22c
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger


Reader Comments (Page 1 of 1)
2-06-2007 @ 4:06PM
Sheldon L said...
I know what GOOG is worth...less tomorrow than it is today!
2-06-2007 @ 8:02PM
beanspants said...
Any investment professional will tell you that past performance is no guarantee of future results, but the metrics used to predict a price target (or future results) are all based on past performance.
""
This doesn't really apply when doing the estimations for future returns from a fundamental value analysis perspective.
I mean, are you really saying that you can't predict R&D or debt expense within 10% from year to year?
And the point Blodgett makes is that estimating future value based on past performance isn't of value, but that's completely ignoring the other 50% of the work done creating that estimate -- it's like saying you could have figured out Einstein's Theory of Relativity because you can work out the equation if the numbers are given to you.
Basically, Blodgett is a hack and a slimeball, and is sad he's getting paid to do such work.